



Practitioner's Docket No. 0152.00391

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Paris, et al

Serial Number: 09/743,781

Group Art Unit: 1614

Filed: 03/28/01

Examiner:

For: MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC

1614
TECH CENTER 1600
RECEIVED
MAY 8 2002
2002
00602600

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR 1.97(e)(1)

Box DD
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Provided herewith are copies of patents and publications as listed in the attached PTO-1449 (supplemental).

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of the statement. 37 CFR 1.97(e)(1).

While the statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The filing of this statement does not mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Please charge our Deposit Account No. 11-1449 for any additional fees or credit our account for any overpayment. **A duplicate of this transmittal is attached.**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington

D.C. 20231, on 4/22/02
(Date of Deposit)
Cil Wolff
Angel Webb
Signature
4/22/02
Date of Signature

Respectfully submitted,

KOHN & ASSOCIATES

Kenneth I. Kohn
Registration No. 30,955
30500 Northwestern Hwy.
Suite 410
Farmington Hills, MI 48334
(248) 539-5050

Date: April 22, 2002